CSIMarket
 
Allena Pharmaceuticals Inc.  (ALNA)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 101
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) -20
 Capital Exp. (TTM) (Millions $) 0

Allena Pharmaceuticals Inc.
Allena Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative solutions for patients suffering from rare and severe metabolic disorders. The company is dedicated to transforming the treatment landscape by targeting underlying metabolic pathways to address unmet needs.

Allena Pharmaceuticals leverages its deep expertise in using enzymes to modulate metabolism, with a focus on designing and developing oral enzyme therapeutics. By targeting specific metabolic pathways, the company aims to develop novel, non-absorbed oral therapeutics that can be administered conveniently and effectively.

The company's pipeline of drug candidates includes potential treatments for hyperoxaluria, a disorder characterized by the overproduction of oxalate, as well as other rare and severe metabolic disorders. Allena Pharmaceuticals is committed to advancing its drug candidates through clinical development stages to ultimately provide patients with effective and safe treatment options.

In summary, Allena Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare and severe metabolic disorders through targeting specific metabolic pathways.


   Company Address: 142-F North Road Sudbury 1776 MA
   Company Phone Number: 467-4577   Stock Exchange / Ticker: NASDAQ ALNA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cyclo Therapeutics Inc

CYTH Sees Impressive Revenue Surge and Deficit Reduction in Q4 2023

Cyclo Therapeutics Inc, a Biotechnology and Pharmaceuticals company, has shown positive growth in the fourth quarter of 2023, despite industry-wide challenges. In its December 31, 2023 report, the company reported a significant revenue rise of 66.699% to $0.31 million. This increase in revenue has helped the company reduce its losses to $-0.18 per share, down from $-0.48 per share in the same reporting season the previous year.
Unlike many other entities in the Biotechnology and Pharmaceuticals sectors, which are experiencing declining top-line and receding transactions, Cyclo Therapeutics Inc has managed to shine in the fourth quarter. This is a positive development for the company, as it signifies its ability to navigate obstacles and maintain growth.

Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc Reports Operating Deficit of $-18.2 Million in Fourth Quarter of 2023

In the world of biotechnology and pharmaceuticals, Calidi Biotherapeutics Inc has recently announced its financial results for the fourth quarter of 2023. The company reported an operating deficit of $-18.246049 million, a significant increase from the operating deficit of $-2.714765 million in the fourth quarter of 2022.
The net deficit for the financial period ending December 31, 2023, was reported at $-20.699 million, a substantial increase from $-2.587 million in the previous year. Despite these losses, the company did not report any revenue for the financial year 2023, with a bottom-line of $-29.22 million.

Coherus Biosciences Inc

Coherus Biosciences Inc Makes Bold Strategic Move in Divesting Ophthalmology Franchise for $170 Million

Coherus Biosciences, a leading biopharmaceutical company, has recently completed the divestiture of its Ophthalmology Franchise with an upfront cash payment of $170 million. This strategic move aims to strengthen the company's capital structure and focus on its core business areas.
The divestiture of Coherus' Ophthalmology Franchise is a significant step towards streamlining its operations and reallocating resources into key therapeutic areas. By divesting the franchise, the company can optimize its business and concentrate on its primary goal of developing innovative and cost-effective treatment options for patients.

Fresh Tracks Therapeutics Inc

2. The Future of Fresh Tracks Therapeutics Inc: Analyzing Financial Results and Market Suspension

Fresh Tracks Therapeutics Inc: Navigating Challenges and Charting a New Course
As an investor and shareholder of Fresh Tracks Therapeutics Inc, I have closely followed the latest financial results and the recent announcement about the company's stock being suspended from trading on The Nasdaq Capital Market. As an avid reader of The , it is my pleasure to share my interpretation and provide some insights into what these developments might mean for the future of the company.
First and foremost, let's delve into the financial results. Fresh Tracks Therapeutics Inc has certainly shown improvement in its recent fiscal period compared to the previous year. The company managed to reduce its losses per share substantially, from $-1.70 to $-0.12. In addition, EPS fell from $0.32 to $-0.12, indicating a decline in profitability. While it is certainly a step in the right direction to cut down losses, it is important to keep an eye on the declining EPS and explore ways to improve it in the future.

Zivo Bioscience Inc

Zivo Bioscience Inc Reports Revenue Growth in Fourth Quarter of 2023

Zivo Bioscience Inc, a leading biotech/agtech RandD company, has recently made headlines with its announcement of a 1-for-6 reverse stock split. This decision comes as the company seeks to address challenges faced by its shareholders and increase investor confidence. By consolidating shares, this move aims to improve stability and potentially boost shareholder value.
The company, specializing in the development of therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, reported revenue of $0.0118 million in the October to December 31, 2023 period. While there was a net shortfall of $-1.909 million during this time frame, it marks an improvement from the previous year's deficit of $-2.641 million. Looking at the financial results for the entire 2023 fiscal year, Zivo Bioscience Inc reported a shortfall of $-7.78 million and revenue of $0.03 million. The net shortfall per share also increased to $-4.60 from $-0.93 in the prior financial year.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com